Cifras calculadas a partir de notificaciones regulatorias oficiales — .
Analistasobjetivo 57 USD (+256%) · consenso 5/5 · 2 compra · 0 mantener · 0 venta
Propiedadiniciados 47.91% · instituciones 12.26% · posiciones cortas 20.7% del flotante
En USD · a Oct 19, 2026
Pregúntale a la máquina
Busca y compara operaciones de iniciados, sociedades y sus estadísticas en lenguaje natural. Tu pregunta se convierte en una consulta sobre los datos disponibles, no en una conversación ni en asesoramiento de inversión.
Solo datos de Greenwich LifeSciences, Inc.. Sin búsqueda web. Se excluyen las estadísticas globales de cada iniciado.
Una búsqueda ejecutada consume un crédito, incluso sin resultados. Los errores y las preguntas no compatibles no consumen créditos.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Fuente de información de mercado · Oct 19, 2026
Identidad según la SEC · Oct 19, 2026
Cronología en el mercado · historial completo
122 compras— precio de cierrebarra = volumen usd, escala √haz clic en un periodo para filtrar la tabla
| Iniciado | Tipo | Valor · USD | Señales | Detalle |
|---|---|---|---|---|
| Patel Snehalhistorial | Compra | $9.2K | conv 29 |
| SEC |
| Patel Snehalhistorial | Compra | $20.4K | conv 29 | SEC |
| Patel Snehalhistorial | Compra | $20.4K | conv 29 | SEC |
| Patel Snehalhistorial | Compra | $14.2K | conv 29 | SEC |
| Patel Snehalhistorial | Compra | $32.9K | conv 35 | SEC |
| Patel Snehalhistorial | Compra | $53.7K | conv 21 | SEC |
| Patel Snehalhistorial | Compra | $79.9K | conv 31 | SEC |
| Patel Snehalhistorial | Compra | $91.8K | conv 39Tamaño inusual | SEC |
| Patel Snehalhistorial | Compra | $63K | conv 17 | SEC |
| Patel Snehalhistorial | Compra | $51.7K | conv 18 | SEC |
| Patel Snehalhistorial | Compra | $38.5K | conv 28 | SEC |
| Patel Snehalhistorial | AsignaciónD (derivado) | n/d (Operación sin contrapartida en efectivo: la notificación indica precio cero (concesión, donación, ejercicio)) | SEC |
| Patel Snehalhistorial | Compra | $89.4K | conv 27 | SEC |
| Patel Snehalhistorial | Compra | $21.3K | conv 32 | SEC |
| Patel Snehalhistorial | Compra | $35.6K | conv 16 | SEC |
| Patel Snehalhistorial | Compra | $48.5K | conv 17 | SEC |
| Patel Snehalhistorial | Compra | $32.8K | conv 16 | SEC |
| Patel Snehalhistorial | Compra | $48K | conv 20 | SEC |
| Patel Snehalhistorial | Compra | $31.3K | conv 26 | SEC |
| Patel Snehalhistorial | Compra | $24.8K | conv 17 | SEC |
| Patel Snehalhistorial | Compra | $14.6K | conv 26 | SEC |
| Patel Snehalhistorial | Compra | $44K | conv 26 | SEC |
| Patel Snehalhistorial | Compra | $23.9K | conv 27 | SEC |
| Patel Snehalhistorial | Compra | $27.3K | conv 28 | SEC |
| Patel Snehalhistorial | Compra | $35.6K | conv 28 | SEC |